A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-30 and is reviewed periodically as new material appears.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
When NBOMes are administered sublingually, numbness of the tongue and mouth followed by a metallic chemical taste was observed, and researchers describe this physical side effect as one of the main discriminants between NBOMe compounds and LSD.
=== Other === A relationship between intra-operative blood transfusion and cancer recurrence has been observed in colorectal cancer. In lung cancer intra-operative blood transfusion has been associated with earlier recurrence of cancer, worse survival rates and poorer outcomes after lung resection. Suppression of the immune system by blood transfusion has been implicated as playing a role in more than 10 different cancer types, through mechanisms involving the innate and adaptive immune system. Five major mechanisms for this include the lymphocyte-T set, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), natural killer cells (NKCs), and dendritic cells (DCs). Blood transfusion may modulate the activity of antitumor CD8+ cytotoxic T lymphocytes (CD8+/CTL), temporal response of Tregs, and the STAT3 signaling pathway. The role of the antitumor immune response in cancer therapeutics was explored historically through the use of bacteria to enhance the antitumor immune response and more recently in cellular Immunotherapy. However, the impact of transfusion-related immunomodulation (TRIM) on cancer progression has not been definitively established and requires further study. In retrospective studies, blood transfusion has been associated with worse outcomes after cytoreductive surgery and HIPEC. However, correlation does not prove causation, and transfused patients often have more complicated surgeries and more underlying cardiopulmonary disease compared to untransfused patients; conclusions should be based on prospective randomized controlled trials.
== Function == The protein encoded by this gene is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated by, and mediates the responses of many cell ligands, such as IL2, IL3, IL7 GM-CSF, erythropoietin, thrombopoietin, and different growth hormones. Activation of this protein in myeloma and lymphoma associated with a TEL/JAK2 gene fusion is independent of cell stimulus and has been shown to be essential for the tumorigenesis. The mouse counterpart of this gene is found to induce the expression of BCL2L1/BCL-X(L), which suggests the antiapoptotic function of this gene in cells. It also transduces prolactin signals to the milk protein genes and is necessary for mammary gland development.
==== 800–899 ==== South Eastern Combined Fire Area Administration (Amendment) (No. 2) Scheme Order 1993 (S.I. 1993/800) Greater London and Kent (County Boundaries) (Variation) Order 1993 (S.I. 1993/805) Pensions Increase (Civil Service Early Retirement Pension Scheme 1992) Regulations 1993 (S.I. 1993/806) Injuries in War (Shore Employments) Compensation (Amendment) Scheme 1992 S.I. 1993/807) Devon Ambulance Service National Health Service Trust Dissolution Order 1993 (S.I. 1993/809) Cornwall Community Healthcare National Health Service Trust Dissolution Order 1993 (S.I. 1993/810) Walsgrave Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/811) Walsgrave Hospital National Health Service Trust Dissolution Order 1993 (S.I. 1993/812) Cornwall Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/813) Westcountry Ambulance Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/814) Reconstitution of the Romney Marsh Levels Internal Drainage Board Order 1993 (S.I. 1993/815) Reconstitution of the Finningley Internal Drainage Board Order 1993 (S.I. 1993/816) Reconstitution of the River Stour (Kent) Internal Drainage Board S.I. 1993/817) Civil Legal Aid (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/818) Advice and Assistance (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/819) Harefield Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/820) Social Security (Contributions) Amendment (No. 5) Regulations 1993 (S.I.
The class B metallo-β-lactamases (MBLs) are found largely in gram-negative bacteria and environmental bacteria. The subclasses of MBL enzymes are B1, B2, and B3. MBLs have diverse enzymatic functions and have the ability to hydrolyze β-lactam antibiotics. The class D β-lactamases (OXA), which hydrolyze oxacillin, provide a good example of the variety of mechanisms that can be used to transfer resistance. The blaOXA genes which encode OXA β-lactamases are found on both chromosomes and plasmids, and they have their natural reservoir in environmental bacteria and deep-sea microflora. Insertions in the vicinity of these genes have been shown to increase the strength of their promoters and increase resistance. Because of these characteristics, a wide geographic dissemination of OXA carbapenemase resistance in particular has occurred. The facilitated spread of carbapenem resistance appears to have multiple origins and repeated introduction into the UK of bacteria with the blaOXA-48 gene via horizontal transfer of similar plasmids to pOXA-48a.
Sources: en.wikipedia.org
== Mode of action == The molecular mechanism of inhibiting mechanosensitive channels by GsMTx-4 is bilayer-dependent. Rather than directly binding to the gating structures like other ICK peptides do, GsMTx4 makes the mechanosensitive channels less sensitive to mechanical tension of the bilayer membrane. By its tension-dependent insertion into the membrane, GsMTx4 is thought to distort the distribution of tension near mechanosensitive channels, which will make the transfer of force from the bilayer to the channel less efficient. Unlike other ICK peptides, the action of GsMTx-4 is not stereospecific, as both L- and D-GsMTx-4 can block MSCs.
In some organisms, the enzyme can use alternative keto acids instead of α-ketoglutaric acid. It has been found in pea, and the genes coding for the enzyme have been studied in Bacillus sphaericus. This enzyme belongs to the family of transferases, specifically the transaminases, which transfer nitrogenous groups. The systematic name of this enzyme class is D-alanine:2-oxoglutarate aminotransferase. Other names in common use include D-aspartate transaminase, D-alanine aminotransferase, D-aspartic aminotransferase, D-alanine-D-glutamate transaminase, D-alanine transaminase, and D-amino acid aminotransferase. This enzyme participates in 6 metabolic pathways: lysine degradation, arginine and proline metabolism, phenylalanine metabolism, D-arginine and D-ornithine metabolism, D-alanine metabolism, and peptidoglycan biosynthesis. It employs one cofactor, pyridoxal phosphate.
== Risks == CJC-1295 was under investigation for the treatment of lipodystrophy and growth hormone deficiency and reached phase II clinical trials but was discontinued upon the death of one of the trial subjects. The attending physician of the trial believed that the most likely explanation for the incident was that the patient had asymptomatic coronary artery disease with plaque rupture and occlusion, and that the occurrence was unrelated to treatment with CJC-1295. Research was terminated nonetheless as a precaution.
Maybe King Crimson will speak to him in the future in some way, and will revive its head with who-knows-what line up?" At a post-screening Q&A session for In the Court of the Crimson King, Fripp referred to the seven-member 2021 line-up of King Crimson as "the final incarnation" of the band. Asked if there could ever be a line-up that did not include him, he answered negatively, stating "I see the whole. I see the music. I see the musicians. I see the audience and I see the music industry [...] and you have to engage with all of that to have the overview. So that's the quick answer".
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.